Resumen
An exciting and emerging field in nanomedicine involves the use of gold nanoparticles (AuNPs) in the preclinical development of new strategies for the treatment and diagnosis of brain-related diseases such as neurodegeneration and cerebral tumors. The treatment of many brain-related disorders with AuNPs, which possess useful physical properties, is limited by the blood–brain barrier (BBB). The BBB highly regulates the substances that can permeate into the brain. Peptides and proteins may represent promising tools to improve the delivery of AuNPs to the central nervous system (CNS). In this review, we summarize the potential applications of AuNPs to CNS disorders, discuss different strategies based on the use of peptides or proteins to improve the delivery of AuNPs to the brain, and examine the intranasal administration route, which bypasses the BBB. We also analyze the potential neurotoxicity of AuNPs and the perspectives and new challenges concerning the use of peptides and proteins to enhance the delivery of AuNPs to the brain. The majority of the work described in this review is in a preclinical stage of experimentation, or in select cases, in clinical trials in humans. We note that the use of AuNPs still requires substantial study before being translated into human applications. However, for further clinical research, the issues related to the potential use of AuNPs must be analyzed.
| Idioma original | English |
|---|---|
| Páginas (desde-hasta) | 4919-4936 |
| Número de páginas | 18 |
| Publicación | International Journal of Nanomedicine |
| Volumen | 10 |
| DOI | |
| Estado | Published - 10 ago 2015 |
Huella dactilar
ASJC Scopus subject areas
- Biophysics
- Bioengineering
- Biomaterials
- Drug Discovery
- Organic Chemistry
Citar esto
}
Peptides and proteins used to enhance gold nanoparticle delivery to the brain : Preclinical approaches. / Velasco-Aguirre, Carolina; Morales, Francisco; Gallardo-Toledo, Eduardo; Guerrero, Simon; Giralt, Ernest; Araya, Eyleen; Kogan, Marcelo J.
En: International Journal of Nanomedicine, Vol. 10, 10.08.2015, p. 4919-4936.Resultado de la investigación: Review article
TY - JOUR
T1 - Peptides and proteins used to enhance gold nanoparticle delivery to the brain
T2 - Preclinical approaches
AU - Velasco-Aguirre, Carolina
AU - Morales, Francisco
AU - Gallardo-Toledo, Eduardo
AU - Guerrero, Simon
AU - Giralt, Ernest
AU - Araya, Eyleen
AU - Kogan, Marcelo J.
PY - 2015/8/10
Y1 - 2015/8/10
N2 - An exciting and emerging field in nanomedicine involves the use of gold nanoparticles (AuNPs) in the preclinical development of new strategies for the treatment and diagnosis of brain-related diseases such as neurodegeneration and cerebral tumors. The treatment of many brain-related disorders with AuNPs, which possess useful physical properties, is limited by the blood–brain barrier (BBB). The BBB highly regulates the substances that can permeate into the brain. Peptides and proteins may represent promising tools to improve the delivery of AuNPs to the central nervous system (CNS). In this review, we summarize the potential applications of AuNPs to CNS disorders, discuss different strategies based on the use of peptides or proteins to improve the delivery of AuNPs to the brain, and examine the intranasal administration route, which bypasses the BBB. We also analyze the potential neurotoxicity of AuNPs and the perspectives and new challenges concerning the use of peptides and proteins to enhance the delivery of AuNPs to the brain. The majority of the work described in this review is in a preclinical stage of experimentation, or in select cases, in clinical trials in humans. We note that the use of AuNPs still requires substantial study before being translated into human applications. However, for further clinical research, the issues related to the potential use of AuNPs must be analyzed.
AB - An exciting and emerging field in nanomedicine involves the use of gold nanoparticles (AuNPs) in the preclinical development of new strategies for the treatment and diagnosis of brain-related diseases such as neurodegeneration and cerebral tumors. The treatment of many brain-related disorders with AuNPs, which possess useful physical properties, is limited by the blood–brain barrier (BBB). The BBB highly regulates the substances that can permeate into the brain. Peptides and proteins may represent promising tools to improve the delivery of AuNPs to the central nervous system (CNS). In this review, we summarize the potential applications of AuNPs to CNS disorders, discuss different strategies based on the use of peptides or proteins to improve the delivery of AuNPs to the brain, and examine the intranasal administration route, which bypasses the BBB. We also analyze the potential neurotoxicity of AuNPs and the perspectives and new challenges concerning the use of peptides and proteins to enhance the delivery of AuNPs to the brain. The majority of the work described in this review is in a preclinical stage of experimentation, or in select cases, in clinical trials in humans. We note that the use of AuNPs still requires substantial study before being translated into human applications. However, for further clinical research, the issues related to the potential use of AuNPs must be analyzed.
KW - Biodistribution
KW - Blood–brain barrier
KW - Central nervous system
KW - Drug delivery
KW - EPR effect
KW - Transcytosis
UR - http://www.scopus.com/inward/record.url?scp=84981717459&partnerID=8YFLogxK
U2 - 10.2147/IJN.S82310
DO - 10.2147/IJN.S82310
M3 - Review article
C2 - 26300639
AN - SCOPUS:84981717459
VL - 10
SP - 4919
EP - 4936
JO - International Journal of Nanomedicine
JF - International Journal of Nanomedicine
SN - 1176-9114
ER -